Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACSI trial
2023-508551-40-00Phase 4Authorised
- Sponsor
- Region Västra Götaland
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 5
01
Overview
Phase 4, randomised trial in acute coronary syndrome (ACS) and coronary arteriosclerosis comparing Dual antiplatelet therapy: ticagrelor + ASA with ASA monotherapy (2 arms). Primary endpoint: Composite of all-cause death, myocardial infarction, stroke, or new coronary revascularization within 12 months. Planned start Oct 2024; status: authorised.
02
Drugs
ticagreloraspirin
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2023-508551-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508551-40-00.